What is triptorelin and how does it work?

Triptorelin (brand name Diphereline) is a gonadotrophin-releasing hormone agonist (GnRHa). Given as a monthly intramuscular injection, it suppresses the pituitary signals that drive oestrogen and progesterone production. This reduces the hormonal environment that feeds endometriosis lesions and stimulates fibroid growth. It is also used in IVF to suppress the pituitary before egg stimulation, and in men for hormone-dependent prostate cancer.

Why does PBS listing matter for patients with endometriosis?

Without a PBS listing, triptorelin costs up to $264 per monthly injection — for a condition typically requiring three to six months or more of treatment, that is $800 to $1,600 or more out of pocket. PBS listing would drop the patient cost to the standard co-payment (approximately $31 for general patients in 2026), removing a significant financial barrier to treatment for a condition that already causes significant delays in diagnosis and access to care.

What about patients currently on Zoladex when it leaves the market in November?

AstraZeneca has committed to providing the monthly Zoladex 3.6 mg implant at no cost from November 2026 for patients without a suitable treatment alternative. This is a manufacturer access program, not a PBS listing, and its long-term continuity is less structurally secure than a subsidised PBS option. Triptorelin PBS listing would provide a more durable pathway — which is why the PBAC convened an accelerated out-of-session review rather than waiting for the next scheduled meeting cycle.

PBAC considers PBS listing for triptorelin in endometriosis and fibroids

What just happened

On 28 July, RACGP reported that the Pharmaceutical Benefits Advisory Committee had called a special out-of-session meeting for 30 July 2026 — an unusual move — to consider adding triptorelin 3.75 mg (Diphereline) to the PBS for women’s health indications, including endometriosis and uterine fibroids.

The trigger was a surge of clinical and consumer submissions following AstraZeneca’s announcement that it would withdraw the low-dose Zoladex (goserelin 3.6 mg) implant from the Australian market in November 2026. Zoladex has been PBS-listed for endometriosis and fibroids for years; its removal created an immediate gap for women who depend on it.

Triptorelin is already available in Australia but is only PBS-funded for hormone-dependent prostate cancer. For women using it for endometriosis, fibroids, or IVF pituitary suppression, the cost without subsidy is up to $264 for a single monthly injection. Three to six months of treatment — a common requirement — can mean $800 to $1,600 entirely out of pocket.

The PBAC’s willingness to convene outside its normal meeting schedule signals how much clinical and community pressure accompanied this request. RACGP NSW&ACT Chair Dr Rebekah Hoffman said it directly: “These things don’t need to take six to 12 months. They can be done in a more timely manner.”

Both-and

What triptorelin and goserelin actually do — and why they matter

Both triptorelin and goserelin are GnRH agonists. They work by continuously stimulating pituitary GnRH receptors, which sounds counterintuitive — but continuous stimulation, unlike the normal pulsatile pattern, causes the receptors to downregulate. The result is a significant reduction in LH and FSH, which in turn drops oestrogen to near-menopausal levels.

For endometriosis, this matters because endometriosis lesions are oestrogen-dependent. Reducing circulating oestrogen suppresses lesion activity, reduces inflammation, and can significantly improve pain — though it does not eliminate lesions and the effect reverses when treatment stops. For fibroids, the same hormonal suppression reduces fibroid size, often used to shrink them ahead of surgery.

This is established, evidence-based medicine — not a fringe intervention. GnRH agonists have been part of the clinical management toolkit for endometriosis for decades.

The cost barrier is the care barrier

The argument for PBS listing is straightforward: if a medication is clinically indicated, evidence-supported, and already available in Australia, the question is not whether patients should have access — it is why that access is currently contingent on whether they can afford $264 per month.

Endometriosis already has one of the most documented access and delay problems in Australian women’s health. An average of 7–12 years from symptom onset to diagnosis has been cited across multiple Australian studies. The financial barrier to GnRH agonist treatment adds another layer to a system that has historically asked women to prove their symptoms before offering them adequate treatment.

The Zoladex withdrawal sharpened this into a policy issue. Dr Hoffman noted: “What it’s done is left patients really fearful that drug companies can do this. So having another medication that’s made by a different manufacturer really gives significant certainty.” The broader message from the clinical community: women’s health subsidies should not be structurally contingent on single-manufacturer decisions.

What the PBAC process actually involves

It is worth being clear about what this meeting was — and what it was not. The out-of-session meeting on 30 July was a consideration step, not a final recommendation. The PBAC reviews the clinical evidence, the cost-effectiveness analysis, and the consumer submissions; it then makes a recommendation to the Health Minister, who makes the final listing decision. The government then negotiates price with the manufacturer before PBS listing takes effect.

This process takes time. The accelerated meeting signals urgency, but patients should not expect an immediate PBS listing. What it does mean is that the case was considered credible enough to warrant expedited review — and that the significant wave of clinical and consumer advocacy made a difference in how quickly that happened.

The IVF angle

Triptorelin is also widely used in IVF protocols for pituitary downregulation before ovarian stimulation. This use is typically transient (days to weeks rather than months) and often embedded in the overall IVF treatment plan. Whether a PBS listing for women’s health indications would affect its availability or cost in the IVF context depends on the specific listing terms the PBAC proposes — which are not yet known.

My two cents

What I want to name here is not just the policy mechanics but what this episode reflects about the system.

Zoladex’s impending exit prompted patient advocacy that was, by all accounts, large and urgent. The RACGP described “a big cry out” and “large numbers of patients” concerned about what would happen to their access. The PBAC responded by pulling an out-of-schedule meeting. That is not how Australian health policy normally works — it usually moves slowly, deliberately, and on its own calendar.

The fact that it moved faster here is evidence that organised, sustained patient and clinician voice changes things. It does not always, and it is not a system people should have to work this hard to navigate. But in this instance, the advocacy mattered.

For women with endometriosis or fibroids currently managing with Zoladex: your GP should already be reviewing your options ahead of November. If triptorelin is clinically appropriate and you are currently paying for it out of pocket, a PBS listing — if it eventuates — would reduce your cost substantially. It is worth keeping this on your radar and following up with your treating team as the PBAC outcome becomes clear.

Verdict: yes — the PBAC taking an out-of-session meeting is a meaningful signal, and PBS access to triptorelin for women’s health indications would remove a real financial barrier to established, evidence-based treatment. Worth watching closely.

Sources cited

PBAC considers PBS access to triptorelin for women’s health. newsGP (RACGP), 28 July 2026. https://www1.racgp.org.au/newsgp/clinical/pbac-considers-pbs-access-to-triptorelin-for-women
Zoladex access at no cost confirmed despite PBS removal. newsGP (RACGP), 21 July 2026. https://www1.racgp.org.au/newsgp/professional/zoladex-access-at-no-cost-confirmed-despite-pbs-re